Manavata Clinical Research Institute | HCG Manavata Cancer Centr

Research site

Site insights

Top conditions

Top treatments

Doxorubicin Hydrochloride
GRC 54276

Data sourced from

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 18 total trials

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have rec...

Breast Cancer
Drug: Trastuzumab Emtansine
Drug: Placebo

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced lymphomas will be done to assess AUR108 safety, tolerability, p...

Relapsed Advanced Lymphomas
Drug: AUR108

This is first in human (FIH) study to a) evaluate the safety and tolerability profile of GRC54276, b) determine the maximum tolerated dose (MTD) and...

Advanced Solid Tumor
Drug: GRC 54276 + Pembrolizumab
Drug: GRC 54276 + Atezolizumab

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cance...

Breast Neoplasms
Drug: Anastrozole
Drug: Tamoxifen

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaci...

Active, not recruiting
Neoplasm Metastasis
Breast Neoplasms
Drug: Imlunestrant
Drug: Abemaciclib

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Carcinoma, Non-Small-Cell Lung
Neoplasm Metastasis
Drug: Carboplatin
Drug: LY3537982

The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with...

Active, not recruiting
Medullary Thyroid Cancer
Drug: Selpercatinib
Drug: Vandetanib

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in particip...

Carcinoma, Non-Small-Cell Lung
Drug: Placebo
Drug: Selpercatinib

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Advanced Breast Cancer
Drug: Fulvestrant
Drug: ARV-471

This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a p...

Active, not recruiting
Solid Tumors Harboring NTRK Fusion
Drug: BAY2757556 (Larotrectinib, Vitrakvi)

In the SAMSON-2 study, the proposed biosimilar HD204 will be compared to its reference product EU-licensed Avastin®. The aim of the study is to demon...

Active, not recruiting
Non-small Cell Lung Cancer
Lung Cancer
Drug: Bevacizumab
Drug: Carboplatin

This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advan...

Active, not recruiting
Ovarian Neoplasms
Fallopian Tube Neoplasms
Drug: Bevacizumab

Trial sponsors

Lilly logo
Roche logo
Loxo Oncology logo
Bayer logo
Eisai logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems